返回
關鍵數據
前收市價
$2.1
開盤價
$2.1
當日範圍
$2.1 - $2.1
52週區間
$0.96 - $4.45
交易量
200
平均成交量
153
每股盈餘 (TTM)
-0.38
股息收益率
--
市值
$242.4M
什麼是 HEALIOS K K？
Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 65 full-time employees. The company went IPO on 2015-06-16. The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.